Ramya Muddasani, D.O., M.S.
Medical Oncologist
Clinical Expertise
- Thoracic Oncology
- Lung Cancer
- Mesothelioma
- Skin Cancer
- Melanoma
Other Languages Spoken
Telugu
Academic Appointments
- Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Lung Cancer
Mesothelioma
Thoracic Oncology
Skin Cancer and Melanoma
Ramya Muddasani, D.O., M.S., is an assistant clinical professor of medical oncology and therapeutics research at City of Hope® Cancer Center Duarte. A hematologist-oncologist by training, Dr. Muddasani chose her specialty because it enables her to develop pioneering technologies that improve the standard of care for patients everywhere.
Dr. Muddasani earned her medical degree from the University of North Texas Health Science Center, then completed a residency in internal medicine at the New York University Long Island School of Medicine and a fellowship in hematology-oncology at City of Hope. From 2020-2021, she served as a hospitalist at City of Hope® Duarte.
In her current research role, Dr. Muddasani – who has co-authored more than a dozen articles in peer-reviewed journals – focuses on research projects related to thoracic and cutaneous malignancies. She is excited to bring her experience to a role that seeks to make a tangible difference in the lives of cancer patients.
Location
Duarte Cancer Center
1500 East Duarte Road
Duarte, CA 91010
Duarte, CA 91010
Education & Experience
- 2017, Doctor of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, Texas
- 2013, Master of Science, University of North Texas Health Science Center, Fort Worth, Texas
- 2024, Hematology/Oncology, City of Hope, Duarte, California
- 2020, Internal Medicine, NYU Grossman Long Island School of Medicine
- 2024-present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California
- 2020-2021, Hospitalist, City of Hope Comprehensive Cancer Center, City of Hope, Duarte, California
Publications
- Muddasani R, Chehrazi-Raffle A, Dizman N, Hsu J, Meza L, Zengin ZB, Malhotra J, Chawla N, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald BR, McDaniel T, Trent JM, Baehner FL, Murtaza M, Pal SK. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2023 Apr;7:e2200543. doi: 10.1200/PO.22.00543. PMID: 37027813.
- Meza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Hsu JA, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Rock A, Liu S, Salgia R, Trent J, Altin J, Pal SK. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. Oncologist. 2023 Mar 27:oyad067. doi: 10.1093/oncolo/oyad067. Epub ahead of print. PMID: 36971500.
- Zengin ZB, Govindarajan A, Salgia N, Sayegh N, Tripathi N, Muddasani R, Chehrazi-Raffle A, Feng M, Mercier BD, Ladbury C, Hao C, Salgia S, Chawla N, Meza L, Malhotra J, Dizman N, Hsu J, Castro DV, Barragan-Carrillo R, Ebrahimi H, Philip EJ, Chang M, Zhang J, Byron S, Lyou Y, Dorff T, Pal SK, Dandapani S. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma. Eur Urol Oncol. 2023 Jan 4:S2588-9311(22)00203-6. doi: 10.1016/j.euo.2022.11.006. Epub ahead of print. PMID: 36609061.
- Chawla NS, Sayegh N, Tripathi N, Govindarajan A, Zengin ZB, Phillip EJ, Dizman N, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Hsu J, Agarwal N, Pal SK, Tripathi A. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. Clin Genitourin Cancer. 2022 Nov 18:S1558-7673(22)00242-7. doi: 10.1016/j.clgc.2022.11.007. Epub ahead of print. PMID: 36509613.
- Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022 Apr;28(4):704-712. doi: 10.1038/s41591-022-01694-6. Epub 2022 Feb 28. PMID: 35228755; PMCID: PMC9018425.
- Zengin ZB, Chehrazi-Raffle A, Salgia NJ, Muddasani R, Ali S, Meza L, Pal SK. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. Urol Oncol. 2022 Feb;40(2):25-36. doi: 10.1016/j.urolonc.2021.10.003. Epub 2021 Nov 26. PMID: 34840077.
- Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021 Sep 1;27(17):4807-4813. 2021 Jun 15. PMID: 34130999.
- Salgia NJ, Chehrazi-Raffle A, Hsu J, Zengin Z, Salgia S, Chawla NS, Meza L, Malhotra J, Dizman N, Muddasani R, Ruel N, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal SK. Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Med. 2021 Aug;10(16):5671-5680. doi: 10.1002/cam4.4119. Epub 2021 Jul 31. PMID: 34331372; PMCID: PMC8366095.
- ▪ Gulati S, Muddasani R, Gustavo Bergerot P, Pal SK. Systemic therapy and COVID19: Immunotherapy and chemotherapy. Urol Oncol. 2021 Apr;39(4):213-220. doi: 10.1016/j.urolonc.2020.12.022. Epub 2020 Dec 26. Review. PubMed PMID: 33451934; PubMed Central PMCID: PMC7762713.
- Muddasani R, Talwar N, Suarez-Londono JA, Braunstein M. Management of atypical chronic lymphocytic leukemia presenting with extreme leukocytosis. Clin Case Rep. 2020 Mar 5;8(5):877-882. doi: 10.1002/ccr3.2773. PMID: 32477538; PMCID: PMC7250984.